Abstract Library

#2938 Rectal Neuroendocrine Tumor with Concomitant Erdheim-Chester Disease: A Rare Case Report

Introduction: Rectal neuroendocrine tumor (NET), a type of rare tumor, is rather rarer when accompanied by non-Langerhans cells histiocytosis named Erdheim-Chester disease (ECD).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Zhang Y, Liu M, Chen L, Guo Y, Chen M,

Keywords: rectal neuroendocrine tumor, Erdheim-Chester disease.,

#2270 Development of Pre-Clinical NEN Models – Limitations and Opportunities

Introduction: Pre-clinical research in neuroendocrine neoplasia (NEN) has long been impaired by the paucity of NET and NEC cell lines. Furthermore, established models have not been widely available or displayed unusual features (eg. p53 and ras mutations, high proliferation rate).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Schrader J

Authors: Schrader J, Benten D, Unrau L, Fahl M, Eggers C,

Keywords: cell line,

#2193 Advanced Gastric Neuroendocrine Carcinoma: A Diagnostic and Management Conundrum

Introduction: Gastric neuroendocrine carcinomas are rare tumors with a high malignant trait and poor prognosis. Endogenous hypercortisolism associated with neuroendocrine carcinomas can have a negative impact on patients' survival.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Lambrescu I, Martin S, Nitipir C, Terzea D, Cima L,

Keywords: gastric neuroendocrine carcinoma, hypercortisolism, Cushing disease, ectopic ACTH,

#2053 Value of Tumor Growth Rate (TGR) as an Early Predictor of Patients’ Outcome in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs): The GREPONET Study

Introduction: TGR (% change in tumour volume per month (%/m)) is postulated to be an early radiological biomarker to overcome limitations of RECIST in NETs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Lamarca A

Authors: Lamarca A, Crona J, Ronot M, Opalinska M, Lopez Lopez C,

Keywords: tumor growth rate, response, progression-free survival, follow-up, neuroendocrine tumor, prognosis, TGR, RECIST, radiology,

#1940 Impact of Concomitant Medication on Efficacy of Telotristat Ethyl – A Post Hoc Subgroup Analysis of the Phase 3 TELESTAR Study in Carcinoid Syndrome

Introduction: The tryptophan hydroxylase inhibitor telotristat ethyl (TE) significantly reduced bowel movement (BM) frequency versus placebo (pbo) in patients (pts) with carcinoid syndrome (CS) in the TELESTAR study.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Anthony L, Kulke M, Hörsch D, Bergsland E, Öberg K,

Keywords: serotonin, diarrhea ,